LY3435151 + Pembrolizumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor
Conditions
Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Cervical Carcinoma, High Grade Serous Ovarian Carcinoma, Hepatocellular Carcinoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma
Trial Timeline
Oct 28, 2019 → Mar 5, 2020
NCT ID
NCT04099277About LY3435151 + Pembrolizumab
LY3435151 + Pembrolizumab is a phase 1 stage product being developed by Eli Lilly for Solid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT04099277. Target conditions include Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04099277 | Phase 1 | Terminated |
Competing Products
20 competing products in Solid Tumor